Table 74Summary evidence profile for olanzapine versus olanzapine + fluoxetine (harm data are for olanzapine + fluoxetine versus olanzapine)

OutcomeAggressionDepressionLeaving treatment earlyLeaving treatment early because of side effectsN reporting side effectsWeight
Clinician-rated effect sizeSMD = 0.02 (−0.71, 0.76)*SMD = 0.39 (−0.35, 1.13)*RD = 0.13 (−0.06, 0.33) 13% versus 0%RD = 0.07 (−0.1, 0.23) 7% versus 0%RD = −0.2 (−0.42, 0.02) 80% versus 100%WMD = −1.5 (−2.91, −0.09)
 Quality of evidenceVery lowVery lowVery lowVery lowVery lowModerate
 Number of studies/participants(K = 1; n = 29)(K = 1; n = 29)(K = 1; n = 31)(K = 1; n = 31)(K = 1; n = 31)(K = 1; n = 29)
Forest plotPharm 03.01Pharm 06.08Pharm 16.04Pharm 17.02Pharm 17.05Pharm 18.02
*

Based on skewed data.

From: 6, PHARMACOLOGICAL AND OTHER PHYSICAL TREATMENTS IN THE MANAGEMENT OF BORDERLINE PERSONALITY DISORDER

Cover of Borderline Personality Disorder
Borderline Personality Disorder: Treatment and Management.
NICE Clinical Guidelines, No. 78.
National Collaborating Centre for Mental Health (UK).
Leicester (UK): British Psychological Society; 2009.
Copyright © 2009, The British Psychological Society & The Royal College of Psychiatrists.

All rights reserved. No part of this book may be reprinted or reproduced or utilised in any form or by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying and recording, or in any information storage or retrieval system, without permission in writing from the publishers. Enquiries in this regard should be directed to the British Psychological Society.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.